Compare KOSS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOSS | BOLD |
|---|---|---|
| Founded | 1953 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | |
| Sector | Consumer Staples | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.3M | 36.5M |
| IPO Year | 1994 | 2024 |
| Metric | KOSS | BOLD |
|---|---|---|
| Price | $4.36 | $1.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 26.3K | ★ 366.0K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.00 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,624,170.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.93 | N/A |
| 52 Week Low | $3.50 | $0.96 |
| 52 Week High | $8.59 | $1.72 |
| Indicator | KOSS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 57.21 | 61.19 |
| Support Level | $4.16 | $1.12 |
| Resistance Level | $4.91 | $1.55 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 47.62 | 52.17 |
Koss Corp is engaged in the design, manufacture, and sale of stereo headphones and related accessory products. It operates in the audio/video industry segment of the home entertainment industry. The company markets a line of headphones, wireless Bluetooth headphones, wireless Bluetooth speakers, computer headsets, telecommunications headsets, and active noise-canceling headphones. The majority of the firm's revenue is derived from sales of stereo headphones. The Company also sells products to distributors for resale to school systems, and directly to other manufacturers for inclusion with their own products.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.